DRP-2 Monoclonal Antibody Blocking Peptide
€363.00
In stock
SKU
AC-BP1131a
Background:
DRP-2, also known as collapsin response mediator protein-2 (CRMP-2), is expressed at high levels in the developing nervous system and plays a critical role in axonal outgrowth by specifying axon/dendrite fate and establishing neuronal polarity (1,2). CRMP-2 enhances axon elongation and branching by binding to tubulin heterodimers to promote microtubule assembly (3). GSK-3? inactivates CRMP-2 by phosphorylating it at Thr514. CRMP-2 is primed following phosphorylation at Ser522 by CDK5 and at Thr518 by GSK-3? (2). Phosphorylation of CRMP-2, which decreases tubulin binding ability, can be inhibited by NT-3 and BDNF through the PI3 kinase/Akt pathway (2). CRMP-2 also mediates semaphorin-induced growth cone collapse (4). Hyperphosphorylation of CRMP-2 and is found in Alzheimer disease plaques with concurrent elevated GSK-3? activity in these patients (5).
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AM1131a was selected from the region of human DRP-2 Monoclonal. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Other Accession: Q16555
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
DRP-2, also known as collapsin response mediator protein-2 (CRMP-2), is expressed at high levels in the developing nervous system and plays a critical role in axonal outgrowth by specifying axon/dendrite fate and establishing neuronal polarity (1,2). CRMP-2 enhances axon elongation and branching by binding to tubulin heterodimers to promote microtubule assembly (3). GSK-3? inactivates CRMP-2 by phosphorylating it at Thr514. CRMP-2 is primed following phosphorylation at Ser522 by CDK5 and at Thr518 by GSK-3? (2). Phosphorylation of CRMP-2, which decreases tubulin binding ability, can be inhibited by NT-3 and BDNF through the PI3 kinase/Akt pathway (2). CRMP-2 also mediates semaphorin-induced growth cone collapse (4). Hyperphosphorylation of CRMP-2 and is found in Alzheimer disease plaques with concurrent elevated GSK-3? activity in these patients (5).
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AM1131a was selected from the region of human DRP-2 Monoclonal. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Other Accession: Q16555
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review